What is Evozyne?
Evozyne specializes in the design of novel therapeutic proteins through the application of generative artificial intelligence. Their proprietary AI-native platform, EvoGen, is engineered to optimize protein sequences for superior potency, stability, specificity, and immunogenicity. Complementing this AI capability is EvoLab, a high-throughput facility dedicated to synthesizing and rigorously testing thousands of protein candidates. This process generates proprietary data that fuels Evozyne's immunology pipeline, with the ultimate goal of developing scalable immune therapies for patients unresponsive to current treatments.
How much funding has Evozyne raised?
Evozyne has raised a total of $81M across 1 funding round:
Series B
$81M
Series B (2023): $81M with participation from Valor Equity Partners, OrbiMed, NVIDIA, Fidelity Investments, and Paragon Biosciences
Key Investors in Evozyne
Valor Equity Partners
Valor Equity Partners, established in 2001 and headquartered in Chicago, Illinois, is an investment firm focused on financial services and investment activities.
OrbiMed
OrbiMed Advisors LLC is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, digital health, diagnostics, and healthcare services. They support companies at various stages of development with a comprehensive understanding of healthcare innovation.
NVIDIA
NVIDIA, a global technology company founded in 1993, specializes in GPUs, computer hardware, and AI computing solutions, powering applications in gaming, data centers, and autonomous vehicles.
What's next for Evozyne?
The recent major strategic investment positions Evozyne for accelerated growth and further development of its AI-driven therapeutic protein pipeline. This backing is expected to fuel advancements in their EvoGen platform and EvoLab operations, enabling the company to expand its research into complex immune-mediated diseases. Evozyne is poised to translate its innovative protein design capabilities into clinical applications, potentially addressing unmet needs in patient populations with limited treatment options. The company's focus on generative AI and high-throughput testing suggests a strategic emphasis on rapid iteration and data-driven discovery in the competitive biopharmaceutical landscape.
See full Evozyne company page
